BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11361961)

  • 1. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
    [No Abstract]   [Full Text] [Related]  

  • 2. Double protease inhibitor regimens with amprenavir show promise.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
    Clark NM; Dieng Sarr A; Sankalé JL; Kanki PJ; Kazanjian P; Winfield R; Markovitz DM
    AIDS; 1998 Dec; 12(18):2506-7. PubMed ID: 9875594
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs.
    Rockstroh JK; Theisen A; Kaiser R; Sauerbruch T; Spengler U
    AIDS; 1998 May; 12(7):829-30. PubMed ID: 9619824
    [No Abstract]   [Full Text] [Related]  

  • 5. Study shows three drugs better than two.
    AIDS Alert; 1997 Apr; 12(4):39. PubMed ID: 11364145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug shows potency against HIV.
    Dent Today; 1996 May; 15(5):22, 26. PubMed ID: 9567867
    [No Abstract]   [Full Text] [Related]  

  • 8. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Larsen L; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    Scand J Infect Dis; 1999; 31(5):489-93. PubMed ID: 10576129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antiretroviral treatment in human immunodeficiency virus infection].
    Blum L; Bachmeyer C
    Ann Dermatol Venereol; 1997; 124(9):641-54. PubMed ID: 9739932
    [No Abstract]   [Full Text] [Related]  

  • 10. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
    Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA
    J Infect Dis; 2000 Sep; 182(3):950-4. PubMed ID: 10950796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indinavir--study highlights importance of CD4+ counts over viral load.
    TreatmentUpdate; 1998 Nov; 10(9):2-3. PubMed ID: 11365923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.
    Lallemand F; Adda N; Schneider V; Jacomet C; Salhi Y; Rozenbaum W
    Clin Infect Dis; 1999 May; 28(5):1184-5. PubMed ID: 10452672
    [No Abstract]   [Full Text] [Related]  

  • 13. Head-to-head study of protease inhibitors.
    AIDS Patient Care STDS; 1998 Jan; 12(1):63-4. PubMed ID: 11361890
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
    Hirsch MS; Steigbigel RT; Staszewski S; McMahon D; Fischl MA; Hirschel B; Squires K; DiNubile MJ; Harvey CM; Chen J; Leavitt RY;
    Clin Infect Dis; 2003 Oct; 37(8):1119-24. PubMed ID: 14523778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
    AIDS Patient Care STDS; 1997 Aug; 11(4):289-90. PubMed ID: 11361848
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saquinavir: major study shows survival benefit in treatment-naive patients.
    James JS
    AIDS Treat News; 1997 Jul; (No 274):6. PubMed ID: 11364463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E
    Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HIV-therapy: as early and as intensive as possible].
    Dtsch Med Wochenschr; 1997 Oct; 122(41):A27. PubMed ID: 9378051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.